Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
AstraZeneca
British-Swedish pharmaceutical company
-
Ionis Pharmaceuticals
American pharmaceutical company
Related events
- Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
- AstraZeneca and Innate Pharma S.A. are collaborating on developing a lead pharmaceutical program.
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.